OKYO Pharma Limited (NASDAQ:OKYO – Get Free Report) traded down 0.4% on Wednesday . The stock traded as low as $1.03 and last traded at $1.04. 47,118 shares traded hands during trading, a decline of 63% from the average session volume of 127,017 shares. The stock had previously closed at $1.04.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of OKYO Pharma in a report on Thursday, October 24th.
View Our Latest Research Report on OKYO
OKYO Pharma Stock Performance
About OKYO Pharma
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.
Read More
- Five stocks we like better than OKYO Pharma
- Why Invest in High-Yield Dividend Stocks?
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- What Does a Stock Split Mean?
- 3 Buy-and-Hold Stocks for Long-Term Growth
- The 3 Best Blue-Chip Stocks to Buy Now
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
